Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been...

ver descrição completa

Detalhes bibliográficos
Autores: Vélez Santamaria, Valentina, Nedkova Hristova, Velina, Díez, Laura, Homedes, Christian, Alberti, Maria Antonia, Casasnovas Pons, Carlos
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/171790
Acesso em linha:https://hdl.handle.net/2445/171790
Access Level:acceso abierto
Palavra-chave:Malalties autoimmunitàries
Malalties neuromusculars
Autoimmune diseases
Neuromuscular diseases
id ES_ee9bf220d6d73ae1fa3f7d5e1036d1ad
oai_identifier_str oai:recercat.cat:2445/171790
network_acronym_str ES
network_name_str España
repository_id_str
spelling Eculizumab as a promising treatment in thymoma-associated myasthenia gravisVélez Santamaria, ValentinaNedkova Hristova, VelinaDíez, LauraHomedes, ChristianAlberti, Maria AntoniaCasasnovas Pons, CarlosMalalties autoimmunitàriesMalalties neuromuscularsAutoimmune diseasesNeuromuscular diseasesMyasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.Sage Publications Ltd.2020202020202020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion4 p.application/pdfhttps://hdl.handle.net/2445/171790Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1177/1756286420932035Therapeutic Advances in Neurological Disorders, 2020, vol. 13https://doi.org/10.1177/1756286420932035cc by-nc (c) Vélez Santamaria et al., 2020http://creativecommons.org/licenses/by-nc/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1717902026-05-29T05:05:01Z
dc.title.none.fl_str_mv Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
spellingShingle Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
Vélez Santamaria, Valentina
Malalties autoimmunitàries
Malalties neuromusculars
Autoimmune diseases
Neuromuscular diseases
title_short Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_full Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_fullStr Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_full_unstemmed Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
title_sort Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
dc.creator.none.fl_str_mv Vélez Santamaria, Valentina
Nedkova Hristova, Velina
Díez, Laura
Homedes, Christian
Alberti, Maria Antonia
Casasnovas Pons, Carlos
author Vélez Santamaria, Valentina
author_facet Vélez Santamaria, Valentina
Nedkova Hristova, Velina
Díez, Laura
Homedes, Christian
Alberti, Maria Antonia
Casasnovas Pons, Carlos
author_role author
author2 Nedkova Hristova, Velina
Díez, Laura
Homedes, Christian
Alberti, Maria Antonia
Casasnovas Pons, Carlos
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Malalties autoimmunitàries
Malalties neuromusculars
Autoimmune diseases
Neuromuscular diseases
topic Malalties autoimmunitàries
Malalties neuromusculars
Autoimmune diseases
Neuromuscular diseases
description Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/171790
url https://hdl.handle.net/2445/171790
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1177/1756286420932035
Therapeutic Advances in Neurological Disorders, 2020, vol. 13
https://doi.org/10.1177/1756286420932035
dc.rights.none.fl_str_mv cc by-nc (c) Vélez Santamaria et al., 2020
http://creativecommons.org/licenses/by-nc/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc (c) Vélez Santamaria et al., 2020
http://creativecommons.org/licenses/by-nc/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 4 p.
application/pdf
dc.publisher.none.fl_str_mv Sage Publications Ltd.
publisher.none.fl_str_mv Sage Publications Ltd.
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423737041846272
score 15,811543

Registos relacionados